It’s a gray Tuesday morning in mid-January 2026. Your HR inbox is stacked with emails from frustrated employees: “Why is my GLP-1 now $1,200? Why won’t my insurance cover my medication anymore?” The GLP-1 coverage cliff has arrived, and the budget decision you made last fall is now a daily reality for you, your workforce and your bottom line.
The decisions employers and their benefits advisors make over the next few months about GLP-1 coverage will vary widely. Some will decide the investment is worth it; others will walk away entirely. And many will try to find a middle ground that keeps costs in check without alienating employees. Here’s how those choices tend to look in practice:
Those keeping full coverage: They’re absorbing the high monthly cost, often $11,000–$15,000 per member per year, because they see GLP-1s as a lever for long-term health, productivity and retention. These employers are betting that keeping employees on proven, FDA-approved medications will prevent costlier claims down the road.
Those ending coverage entirely: They’ll save money in the short term, but they’re bracing for employee backlash and a likely migration to cheaper, compounded versions of GLP-1s. These compounded products lack FDA oversight and can carry safety risks, creating a different kind of exposure for the employer. Suddenly, their financially motivated choice to end coverage becomes a costly mistake, as employees panic and head to expensive emergency room visits to address their 10/10 abdominal pains from compounded and/or black market medications. Additionally, this further opens up a myriad of concerns for employees of color, who are disproportionately impacted by obesity conditions, and thus have been (or will be) hit especially hard by ending coverage.
Those looking for middle ground: They’re exploring partial coverage, step therapy, or alternative pathways. Done poorly, they can frustrate employees and push them to unsafe options, driving the very health costs employers and advisors are trying to avoid. Even if done well, these models may only be in effect for one or two years at a time, temporarily keeping high-risk employees on effective medications while managing budget impact.
The real-world stakes
GLP-1s often cost $1,000 or more per month, and for many self-insured employers, that price tag is the tipping point. But most coverage models miss the full picture. They weigh the drug cost in isolation and fail to account for the long-term savings from avoided claims and productivity gains. That blind spot is why many coverage cuts end up costing more in the long run. Obesity already costs U.S. employers about $347.5 billion annually in healthcare and lost productivity. When safe, reliable access disappears, employees may turn to compounded or black-market versions, where quality is inconsistent, dosages can be wrong, there are higher chances of adverse effects such as suicidality, and active ingredients may not even match the label. One severe adverse reaction, the kind that ends in the ER and requires days off work, can quickly erase any savings.
The stakes go beyond health costs. In a competitive labor market, benefits send a clear message about an employer’s values. Nearly 40% of millennials and 35% of Gen Z say GLP-1 access would improve their job satisfaction. An increasing number of employees say they would take a new job if it came with GLP-1 coverage. Beyond generational trends, access to GLP-1s is quickly becoming a premium benefit that top performers and high-value talent segments use to compare employers. Lose coverage, and employers may also lose top performers to organizations willing to treat it as a premium benefit, a turnover cost few companies can afford to ignore.
A practical playbook for 2026
For employers and their benefits advisors, the question isn’t just whether to cover GLP-1s. It’s how to manage the change without creating bigger problems down the road. Here are three moves that can help you get ahead of the disruption:
1. Audit the at-risk population nowRun the numbers on who’s currently using GLP-1s, why they were prescribed, and what’s at stake if coverage changes. Look beyond claims data. High-risk, high-value employees may be the ones most affected. Understanding that profile now gives you room to make intentional choices instead of scrambling later.
2. Create a safe landing zone for those losing coverage
When employees lose access to FDA-approved GLP-1s, many will turn to compounded versions from online or local pharmacies. Some of these products are safe and legitimate; many are not. The risks include incorrect dosing, contamination, untested formulations, and in some cases, entirely different molecules — for example, semaglutide in place of tirzepatide — that can cause gastrointestinal effects or render the treatment ineffective. Many of these compounded sources look legitimate to the untrained eye, making clear employer guidance even more critical. A clear, credible communication plan, including guidance from clinical experts, can reduce those risks while showing employees you take their health seriously.
3. Integrate alternatives, not just exclusionsIf full coverage is off the table, give employees other routes to address weight and related conditions. That could include partial coverage with clear clinical criteria, wraparound programs for side-effect management and habit change, or access to nutrition, behavioral health, and metabolic care services. Middle-ground models like these can work, but only when executed well. Poorly designed programs risk frustrating employees and pushing them toward unsafe alternatives. The goal is to show that a change in GLP-1 benefits isn’t the same as ending support altogether.
The leadership moment
Coverage decisions about GLP-1s aren’t just about cost, they’re also about brand. The way coverage is structured signals what a company values: short-term savings, long-term health, or both. Employers and advisors who approach plan design with diligence and data-driven strategies will fare far better than those who do not prioritize balancing immediate needs with sustainable, long-term impact.
Assess risk early, protect employees from unregulated alternatives, and offer credible support pathways. These actions strengthen budgets, health outcomes, and talent retention. In a year when benefits decisions will be under a microscope, foresight here can deliver lasting returns.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.